Pharmaceuticals

Recent governmental report on the UK Life Sciences Sector A report to the UK government[1] has recently published, with the aim of bringing into focus the next 20 years of UK government policy in the ‘health life sciences’ sector. In the context of the report, ‘health life sciences’ refers to the application of biology and… Read more »

In response to an opposition by chemicals company BASF, Craig Turner, a partner in our Chemistry, Biotechnology and Pharmaceutical patents team, successfully defended Lycored’s European patent which protects their unique lycopene formulation, used for providing stable red colouring for foods, cosmetics and pharmaceuticals. Longstanding client Lycored are a market-leader in the development and supply of research-based,… Read more »

Background Napp Pharmaceuticals (Napp) is the proprietor of a European (UK) patent, EP2305194B (the Patent), which provides protection for transdermal buprenorphine patches. Napp have marketed buprenorphine patches under the trade name “BuTrans®” since 2005. Both Sandoz and Dr Reddy’s were preparing to launch generic transdermal buprenorphine patches in the UK, but Sandoz were the first… Read more »

From 1 April 2013 onwards, the cost of patenting will be outweighed by patent-related tax savings for many UK companies.

Christopher Burnett, Patent Attorney attended the Global Pharma IP Forum at the London Stock Exchange on 28 September.